If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends on what the new normal looks like, suggest Goodwin Technology and Life Sciences partners Sophie McGrath and Tim Worden. Read the article in In Vivo here.
Related Content
- Life Sciences PerspectivesJuly 8, 2025
A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2025 and Beyond
- Life Sciences PerspectivesJuly 7, 2025
One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry
- AlertJuly 7, 2025
One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry
- Big Molecule WatchJuly 3, 2025
EMA Adopts Positive Opinions for Multiple Biosimilars
- AlertJuly 3, 2025
Changes to Birthright Citizenship and the Impact on Fertility and Assisted Reproduction Clinics
- Big Molecule WatchJuly 2, 2025
Amgen Files BPCIA Complaints Against Biocon, Shanghai Henlius/Organon and Hikma/Gideon Richter Regarding Denosumab Biosimilars
- Big Molecule WatchJune 30, 2025
Kashiv BioSciences Reports Positive Topline Results for XOLAIR® Biosimilar Candidate ADL-018
- Big Molecule WatchJune 28, 2025
BioNTech Announces Transaction to Acquire CureVac
- Press ReleaseJuly 9, 2025
Goodwin Advises Nektar Therapeutics on Closing of $115 Million Public Offering
- Press ReleaseJuly 8, 2025
Goodwin Guides Kymera Therapeutics in $750 Million Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders with Gilead Sciences
- Awards and RankingsJuly 7, 2025
Goodwin Is Number One Law Firm for Global M&A for H1 2025
- In the PressJuly 3, 2025
Delaware Court Awards More Than $180 Million for Breach of Commercially Reasonable Efforts Obligation in Drug Development Milestone Dispute (Westlaw Today)
- Press ReleaseJuly 1, 2025
Goodwin Advised Landmark Bio in Acquisition by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies
- Press ReleaseJuly 1, 2025
SpringWorks Therapeutics Completes Acquisition by Merck KGaA, Darmstadt, Germany to Accelerate Sustainable Growth for $3.9 Billion
- Press ReleaseJune 27, 2025
Goodwin Advises ProFound Therapeutics on Strategic Collaboration with Novartis of up to $750 Million for Cardiovascular Drug Discovery
- Press ReleaseJune 26, 2025
Goodwin Advises Royalty Pharma in Transactions to Provide up to $2 Billion in Funding to Revolution Medicines